Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Survival in Thyroid Cancer in Sweden From 1999 To 2018

F. Zitricky, A. Koskinen, K. Sundquist, J. Sundquist, V. Liska, A. Försti, A. Hemminki, K. Hemminki

. 2024 ; 16 (-) : 659-671. [pub] 20241002

Status neindexováno Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002429

INTRODUCTION: Thyroid cancer (TC) is diagnosed in several histological types which differ in their clinical characteristics and survival. We aim to describe how they influence TC survival in Sweden. METHODS: Cancer data were obtained from the Swedish cancer registry between years 1999 and 2018, and these were used to analyze relative survival. RESULTS: Relative survival for all TC improved when analyzed in 10-year periods, and female survival improved more than male survival. Female survival advantage appeared to be present also for specific histological types, although case numbers were low for rare types. Female 5-year relative survival for TC was 100% for follicular, 95.1% for oncocytic, 93.4% for papillary, 89.7% for medullary, and 6.1% for anaplastic cancer. Among the clinical TNM classes, only T4 and M1 stages were associated with decreased survival compared to T1-3 and M0. Anaplastic cancer presented most often at high T and M1 stages, in contrast to other TC. Curiously, the diagnostic age for anaplastic M1 patients was lower than that for M0 patients. Both anaplastic and medullary cancers did not show age-dependent increases in the probability of metastases, in contrast to the main histological types. This could indicate the presence of several types of anaplastic and medullary cancers. CONCLUSION: The poor survival for anaplastic TC is an extreme contrast to the excellent survival of differentiated TC. As less than 20% of anaplastic cancer patients survived one year, urgent diagnosis and initiation of treatment are important. Facilitated treatment pathways have been instituted in Denmark resulting in improved survival. Anaplastic cancer should be a target of a major research focus.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002429
003      
CZ-PrNML
005      
20250123101932.0
007      
ta
008      
250117e20241002nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/CLEP.S467874 $2 doi
035    __
$a (PubMed)39371051
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Zitricky, Frantisek $u Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czech Republic
245    10
$a Survival in Thyroid Cancer in Sweden From 1999 To 2018 / $c F. Zitricky, A. Koskinen, K. Sundquist, J. Sundquist, V. Liska, A. Försti, A. Hemminki, K. Hemminki
520    9_
$a INTRODUCTION: Thyroid cancer (TC) is diagnosed in several histological types which differ in their clinical characteristics and survival. We aim to describe how they influence TC survival in Sweden. METHODS: Cancer data were obtained from the Swedish cancer registry between years 1999 and 2018, and these were used to analyze relative survival. RESULTS: Relative survival for all TC improved when analyzed in 10-year periods, and female survival improved more than male survival. Female survival advantage appeared to be present also for specific histological types, although case numbers were low for rare types. Female 5-year relative survival for TC was 100% for follicular, 95.1% for oncocytic, 93.4% for papillary, 89.7% for medullary, and 6.1% for anaplastic cancer. Among the clinical TNM classes, only T4 and M1 stages were associated with decreased survival compared to T1-3 and M0. Anaplastic cancer presented most often at high T and M1 stages, in contrast to other TC. Curiously, the diagnostic age for anaplastic M1 patients was lower than that for M0 patients. Both anaplastic and medullary cancers did not show age-dependent increases in the probability of metastases, in contrast to the main histological types. This could indicate the presence of several types of anaplastic and medullary cancers. CONCLUSION: The poor survival for anaplastic TC is an extreme contrast to the excellent survival of differentiated TC. As less than 20% of anaplastic cancer patients survived one year, urgent diagnosis and initiation of treatment are important. Facilitated treatment pathways have been instituted in Denmark resulting in improved survival. Anaplastic cancer should be a target of a major research focus.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Koskinen, Anni $u Department of Otorhinolaryngology- Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland $u Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
700    1_
$a Sundquist, Kristina $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA $u Center for Community-Based Healthcare Research and Education (Cohre), Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan
700    1_
$a Sundquist, Jan $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA $u Center for Community-Based Healthcare Research and Education (Cohre), Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan $1 https://orcid.org/0000000172285015
700    1_
$a Liska, Vaclav $u Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czech Republic $u Department of Surgery, Charles University Medical School, Pilsen, Czech Republic
700    1_
$a Försti, Asta $u Hopp Children's Cancer Center (Kitz), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany $1 https://orcid.org/0000000298574728
700    1_
$a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland $u Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland $1 https://orcid.org/0000000171038530
700    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czech Republic $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $1 https://orcid.org/0000000227693316 $7 mzk20201092711
773    0_
$w MED00165237 $t Clinical epidemiology $x 1179-1349 $g Roč. 16 (20241002), s. 659-671
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39371051 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101926 $b ABA008
999    __
$a ok $b bmc $g 2254571 $s 1238432
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 16 $c - $d 659-671 $e 20241002 $i 1179-1349 $m Clinical epidemiology $n Clin Epidemiol $x MED00165237
LZP    __
$a Pubmed-20250117
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace